Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

Investing for the Future

Thank you for attending our event

Watch the replay

Thank you for joining us and special guest, Leo Johnson, Head of PwC's Disruption practice and co-presenter of Radio 4’s flagship series FutureProofing, as we discussed what lies around the corner for investors. We covered whether ESG is moving from acceptance to dominance, novel treatments within biotechnology, and the implications of transitioning to a new energy system and the clean economy more broadly. Leo passionately explored the big ideas that will shape business and society in the years to come and how the world might respond to this. We believe these trends will have a positive transformative impact on the world and, at a time when growth may be hard to come by, potentially represent a golden opportunity for investors.

Download presentations

David Page - Macro update
Download presentation (447.61 KB)
Amanda O’Toole - Clean Economy
Download presentation (1.48 MB)
Linden Thomson and Peter Hughes - Biotech and Health
Download presentation (1.55 MB)

Visit our fund centre

Find detailed information on our full range of funds, including performance, prices, and commentary from fund managers.

Funds
AXA Framlington Biotech Fund

The aim of this Fund is to provide long-term capital growth.

View funds
Funds
AXA ACT Framlington Clean Economy

The aim of this Fund is to: (i) provide long-term capital growth over a period of 5 years or more; and (ii) seek to achieve sustainable investment objective, in line with a responsible investment approach.

View funds

Guest speaker: Leo Johnson

Image

Leo Johnson, Head of PwC's Disruption practice, co-presents Radio 4’s flagship series FutureProofing, exploring the big ideas and innovations reshaping business and society. He explores the cutting edge in exponential technology, probing game changers both short term and long, from autonomous transport and payment by data to radical life extension, quantum computing, and the RFID chipped workforce. What - in the tsunami of exponential technology - is real and what is hype? More importantly, what is the impact going to be on business?

After Oxford and INSEAD, Leo joined the World Bank as a Resource Economist before co-founding the boutique advisory firm Sustainable Finance, since acquired by PwC Group. He is now a Visiting Business Fellow at Oxford University's Smith School of Enterprise & the Environment, and a regular presenter for BBC World.

Leo is an occasional commentator for the Financial Times, New Statesman, Evening Standard and Wall Street Journal. He also co-authored Turnaround Challenge: Business & the City of the Future.

Amanda O'Toole

Image

Amanda is the lead manager on the Clean Economy fund. She is also the co-manager of the Global Thematics fund and the Clean Tech thematic specialist within our internal global research team. Amanda was previously a member of the Emerging Markets team with a focus on energy, utilities, consumer and healthcare. Prior to joining AXA IM in 2011, Amanda was an Investment Analyst at Nevsky Capital, covering Europe and then Emerging Markets across a range of sectors with emphasis on energy, utilities and consumer. Amanda began her career at PricewaterhouseCoopers, initially in Corporate Recovery and latterly in Corporate Finance.  She holds a BA (Hons) in Economics from the University of Newcastle Upon Tyne and is an Associate Chartered Accountant.

Linden Thomson

Image

As a portfolio manager at Framlington Equities, Linden has been responsible for managing the Biotechnology strategies since 2011. She is also the global biotechnology sector specialist within our internal research organisation. Prior to AXA IM, Linden worked at the hedge fund Clear River Capital, where she was responsible for fundamental stock research across the global pharmaceutical and biotechnology sectors. Linden started her career in 2003 at Goldman Sachs on the sell side in the Healthcare Research team with specific focus on the biotechnology sector. Linden holds a Bachelor’s degree in Medical Microbiology from Edinburgh University. She is also a CFA charterholder.

Peter Hughes

Image

Peter is a Portfolio Manager in our Framlington Equities expertise and has specialised in biotech and longevity within its global strategies since joining the firm in 2015. Prior to AXA IM, Peter worked at Architas in roles covering investment research and relationship man-agement. Peter completed a PhD in biochemistry at University College London, working on a drug development project in a multidisciplinary research group collaborating with GSK. He has a master’s degree in chemistry from the University of Surrey and holds the Investment Management Certificate. He is also an ambassador for the Royal Marsden Cancer Charity.

Related articles

Equities

Clean Economy strategy - September 2022

  • by Amanda O’Toole
  • 03 November 2022 (5 min read)
Equities

Breaking the cycle on International E-Waste Day

  • by Tu Quynh Ly
  • 14 October 2022 (5 min read)
Equities

Why clean energy is a hot topic

    Disclaimer

    Not for retail distribution This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment.

    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee that forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested.